https://www.selleckchem.com/products/aunp-12.html
Six months after the 164 patients in this study had switched to semaglutide, their mean HbA1c had decreased by 0.65% (7.1mmol/mol) (95% prediction interval [PI] 0.48, 0.81% [5.2, 8.9mmol/mol]) from a baseline of 7.9% (interquartile range [IQR] 7.3, 8.8) (62.8mmol/mol [IQR 56.3, 72.7]), while their weight and BMI had reduced by 1.69kg (95%PI 1.01, 2.37) and 0.59kg/m (95%PI 0.34, 0.84), respectively. Nineteen patients (11.6%) developed GSEs after switching. This study supports switching T2DM patients on liraglutide or dulaglutide to injec
Like
Comment
Share
